AMD Expands Ecosystem Partnerships and Product Lineup Amid Market Recovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 hours ago
0mins
Should l Buy AMD?
Source: Benzinga
- Partnership Expansion: AMD deepens its collaboration with BlackBerry QNX, with the Ryzen Embedded V2000 processor being the first to support the platform, which is expected to enhance system reliability in automotive, industrial equipment, and medical imaging sectors, thereby strengthening market competitiveness.
- Developer Tools Available: Developers can now access the necessary tools to start building applications using the supported hardware, a move that will accelerate the market launch of new products and meet the high-performance computing demands across various industries.
- Stock Price Recovery: After a 3.9% decline, AMD's stock rebounded by 0.40% to $203.50 on Monday, reflecting investor concerns over geopolitical tensions and new export policies while also indicating market confidence in AMD's latest product and licensing developments.
- Licensing Deal Resolves Litigation: The licensing agreement reached between AMD and Adeia resolves related litigation, further solidifying AMD's position in the semiconductor industry and is expected to provide more security for future business development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMD
Wall Street analysts forecast AMD stock price to rise
33 Analyst Rating
25 Buy
8 Hold
0 Sell
Strong Buy
Current: 202.680
Low
210.00
Averages
289.13
High
377.00
Current: 202.680
Low
210.00
Averages
289.13
High
377.00
About AMD
Advanced Micro Devices, Inc. is a global semiconductor company. The Company is focused on high-performance computing, graphics and visualization technologies. Its segments include Data Center, Client and Gaming, and Embedded. Data Center segment includes artificial intelligence (AI) accelerators, microprocessors (CPUs) for servers, graphics processing units (GPUs), accelerated processing units (APUs), data processing units (DPUs), Field Programmable Gate Arrays (FPGAs), smart network interface Cards (SmartNICs) and Adaptive system-on-Chip (SoC) products for data centers. Client and Gaming segment includes CPUs, APUs, chipsets for desktops and notebooks, discrete GPUs, and semi-custom SoC products and development services. Embedded segment includes embedded CPUs, GPUs, APUs, FPGAs, system on modules (SOMs), and Adaptive SoC products. It markets and sells its products under the AMD trademark. Its products include AMD EPYC, AMD Ryzen, AMD Ryzen PRO, Virtex UltraScale+, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Recent Updates on AMD and Other AI Stocks
- Video Update: Today's video discusses recent updates affecting AMD and other AI stocks, providing in-depth analysis of market trends to help investors seize investment opportunities.
- Market Reaction: Based on after-market prices from March 5, 2026, AMD shares rose by 0.27%, indicating ongoing market interest in AI technology and a recovery in investor confidence.
- Investment Advice: The video advises investors to focus on potential growth in the AI sector, particularly as companies like AMD continue to launch new technologies and products, which could yield substantial returns.
- Subscription and Offers: The video encourages viewers to subscribe to the channel and click on the special offer link for more market analysis and investment advice, enhancing viewers' investment decision-making capabilities.
See More
Nvidia Stock Rises as AI Platform Sparks Investor Interest
- Stock Price Increase: Nvidia's stock rose by 1.16% to close at $184.77, reflecting investor optimism regarding the expansion of its enterprise AI software platform, which is expected to drive future revenue growth.
- Increased Trading Volume: Today's trading volume reached 177.6 million shares, exceeding the three-month average by 0.6%, indicating sustained market interest and activity surrounding Nvidia's stock.
- New Platform Launch: Nvidia plans to introduce an open-source AI agent platform named 'NemoClaw,' aimed at enhancing its competitiveness in the growing AI tools market, which is expected to attract more software companies to utilize its technology.
- GTC 2026 Conference Outlook: Investors are looking forward to more insights from CEO Jensen Huang at the upcoming GTC 2026 developers conference next week, which could further boost stock prices and enhance market confidence.
See More
Nvidia Stock Rises as AI Platform Sparks Investor Interest
- Stock Performance: Nvidia closed at $184.77, up 1.16%, reflecting investor optimism surrounding its expanding enterprise AI software platform, with expectations for more insights at the upcoming GTC 2026 conference.
- Trading Volume: The trading volume reached 177.6 million shares, approximately 0.6% above the three-month average of 176.6 million shares, indicating sustained market interest and activity in Nvidia's stock.
- New Platform Launch: Nvidia plans to introduce an open-source AI agent platform named 'NemoClaw', which is expected to transition the company from a hardware provider to a key player in software solutions, enhancing its competitiveness in the growing AI tools market.
- Investment Advisory: Despite Nvidia's impressive past performance, the Motley Fool Stock Advisor analyst team did not include it in their current list of top investment stocks, advising investors to consider this before making purchasing decisions.
See More
Microsoft Backs Anthropic Against Pentagon Ban
- Legal Support Statement: Microsoft stated in a court filing in San Francisco that it supports Anthropic's request for a temporary restraining order to block the Pentagon's designation of it as a supply chain risk, aiming to avoid disruptions to the military's use of advanced AI and ensure operational continuity.
- Potential Impact Warning: Microsoft warned that without the order, tech companies would need to immediately alter existing product and contract configurations with the Defense Department, which could hinder U.S. warfighters' capabilities at a critical time, highlighting the close ties between technology and defense.
- Investment Background: Microsoft announced plans to invest up to $5 billion in Anthropic last November, demonstrating its long-term confidence in the company and reflecting its strategic positioning in the AI sector, particularly in defense-related technology applications.
- Negotiation Breakdown: Despite recent negotiations between Anthropic and the Defense Department over contract terms, talks collapsed due to disagreements on model usage, escalating tensions and impacting Anthropic's business outlook.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Stake Sale Overview: On February 17, 2026, BLKBRD Asset Management disclosed it sold all 318,666 shares of Hims & Hers Health, with an estimated transaction value of $18.07 million, reflecting a complete exit from its position during the fourth quarter.
- Impact on Asset Management: This sale reduced Hims & Hers' stake from 5% to 0%, indicating a significant loss of confidence from BLKBRD, which could negatively influence market perceptions of Hims & Hers.
- Stock Performance: As of February 16, 2026, Hims & Hers shares were priced at $16.30, down 72.46% over the past year, underperforming the S&P 500 by 84.25 percentage points, highlighting severe competitive challenges.
- Future Outlook: Although Hims & Hers recently announced a new partnership with Novo Nordisk that may provide a short-term stock rebound, ongoing market pressures and competitive challenges suggest that investors should carefully assess the company's long-term prospects.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Complete Exit: On February 17, 2026, BLKBRD Asset Management disclosed it fully exited its position in Hims & Hers Health by selling 318,666 shares, with an estimated trade value of $18.07 million, resulting in a 24.3% drop in the fund's quarterly average assets under management (AUM).
- Value Decline: The liquidation left Hims & Hers Health with a net position value of zero, previously accounting for 5.0% of the fund's AUM, indicating a complete loss of confidence in the stock by the fund.
- Market Reaction: Hims & Hers' stock has been in freefall since last June, plummeting from a historical high of $64 to around $15, primarily due to Novo Nordisk terminating its partnership and suing the company, which negatively impacted market expectations for its future.
- New Partnership Opportunity: Despite these challenges, Hims & Hers announced a new partnership with Novo Nordisk on March 10, 2026, to offer its weight-loss drugs Ozempic and Wegovy, leading to a 6% stock price increase and providing investors with a chance to reassess the company's prospects.
See More
Recent Updates on AMD and Other AI Stocks
- Video Update: Today's video discusses recent updates affecting AMD and other AI stocks, providing in-depth analysis of market trends to help investors seize investment opportunities.
- Market Reaction: Based on after-market prices from March 5, 2026, AMD shares rose by 0.27%, indicating ongoing market interest in AI technology and a recovery in investor confidence.
- Investment Advice: The video advises investors to focus on potential growth in the AI sector, particularly as companies like AMD continue to launch new technologies and products, which could yield substantial returns.
- Subscription and Offers: The video encourages viewers to subscribe to the channel and click on the special offer link for more market analysis and investment advice, enhancing viewers' investment decision-making capabilities.
See More
Nvidia Stock Rises as AI Platform Sparks Investor Interest
- Stock Price Increase: Nvidia's stock rose by 1.16% to close at $184.77, reflecting investor optimism regarding the expansion of its enterprise AI software platform, which is expected to drive future revenue growth.
- Increased Trading Volume: Today's trading volume reached 177.6 million shares, exceeding the three-month average by 0.6%, indicating sustained market interest and activity surrounding Nvidia's stock.
- New Platform Launch: Nvidia plans to introduce an open-source AI agent platform named 'NemoClaw,' aimed at enhancing its competitiveness in the growing AI tools market, which is expected to attract more software companies to utilize its technology.
- GTC 2026 Conference Outlook: Investors are looking forward to more insights from CEO Jensen Huang at the upcoming GTC 2026 developers conference next week, which could further boost stock prices and enhance market confidence.
See More
Nvidia Stock Rises as AI Platform Sparks Investor Interest
- Stock Performance: Nvidia closed at $184.77, up 1.16%, reflecting investor optimism surrounding its expanding enterprise AI software platform, with expectations for more insights at the upcoming GTC 2026 conference.
- Trading Volume: The trading volume reached 177.6 million shares, approximately 0.6% above the three-month average of 176.6 million shares, indicating sustained market interest and activity in Nvidia's stock.
- New Platform Launch: Nvidia plans to introduce an open-source AI agent platform named 'NemoClaw', which is expected to transition the company from a hardware provider to a key player in software solutions, enhancing its competitiveness in the growing AI tools market.
- Investment Advisory: Despite Nvidia's impressive past performance, the Motley Fool Stock Advisor analyst team did not include it in their current list of top investment stocks, advising investors to consider this before making purchasing decisions.
See More
Microsoft Backs Anthropic Against Pentagon Ban
- Legal Support Statement: Microsoft stated in a court filing in San Francisco that it supports Anthropic's request for a temporary restraining order to block the Pentagon's designation of it as a supply chain risk, aiming to avoid disruptions to the military's use of advanced AI and ensure operational continuity.
- Potential Impact Warning: Microsoft warned that without the order, tech companies would need to immediately alter existing product and contract configurations with the Defense Department, which could hinder U.S. warfighters' capabilities at a critical time, highlighting the close ties between technology and defense.
- Investment Background: Microsoft announced plans to invest up to $5 billion in Anthropic last November, demonstrating its long-term confidence in the company and reflecting its strategic positioning in the AI sector, particularly in defense-related technology applications.
- Negotiation Breakdown: Despite recent negotiations between Anthropic and the Defense Department over contract terms, talks collapsed due to disagreements on model usage, escalating tensions and impacting Anthropic's business outlook.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Stake Sale Overview: On February 17, 2026, BLKBRD Asset Management disclosed it sold all 318,666 shares of Hims & Hers Health, with an estimated transaction value of $18.07 million, reflecting a complete exit from its position during the fourth quarter.
- Impact on Asset Management: This sale reduced Hims & Hers' stake from 5% to 0%, indicating a significant loss of confidence from BLKBRD, which could negatively influence market perceptions of Hims & Hers.
- Stock Performance: As of February 16, 2026, Hims & Hers shares were priced at $16.30, down 72.46% over the past year, underperforming the S&P 500 by 84.25 percentage points, highlighting severe competitive challenges.
- Future Outlook: Although Hims & Hers recently announced a new partnership with Novo Nordisk that may provide a short-term stock rebound, ongoing market pressures and competitive challenges suggest that investors should carefully assess the company's long-term prospects.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Complete Exit: On February 17, 2026, BLKBRD Asset Management disclosed it fully exited its position in Hims & Hers Health by selling 318,666 shares, with an estimated trade value of $18.07 million, resulting in a 24.3% drop in the fund's quarterly average assets under management (AUM).
- Value Decline: The liquidation left Hims & Hers Health with a net position value of zero, previously accounting for 5.0% of the fund's AUM, indicating a complete loss of confidence in the stock by the fund.
- Market Reaction: Hims & Hers' stock has been in freefall since last June, plummeting from a historical high of $64 to around $15, primarily due to Novo Nordisk terminating its partnership and suing the company, which negatively impacted market expectations for its future.
- New Partnership Opportunity: Despite these challenges, Hims & Hers announced a new partnership with Novo Nordisk on March 10, 2026, to offer its weight-loss drugs Ozempic and Wegovy, leading to a 6% stock price increase and providing investors with a chance to reassess the company's prospects.
See More
